The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University Court of the University of Aberdeen

P2d, Inc.

University of Hawai'i

Universitätsklinikum Freiburg

William Douglas Figg

Nigel H Greig

Arnold Brossi

Harold W Holloway

Qian-Sheng Yu

Weiming Luo

David Tweedie

Xiaoxiang Zhu

Neil Vargesson

Shaunna Beedie

Tony Giordano

Kurt Eger

Michael E Weiss

Sunna Hauschildt

Alex Sparreboom

Uwe Teubert

Michael Guetschow

Tristan M Sissung

Thomas Hecker

Kirk R Gustafson

James Brislin McMahon

Martin John Schnermann

John A Beutler

Paresma R Patel

William J Chain

Joe William Ramos

Erin Gardner

David Fash

Agnieszka Ambrozak

Zhenwu Li

Cody John Peer

Michael Gutschow

Susanna T S Chan

Florian J Sulzmaier

Klaus Mross

Dirk Behringer

Akinobu Hamada

Stephan Mielke

Douglas K Price

Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.

Thalidomide analogs and methods of use

Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 &#x3b1; subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.

Hypoxia-inducible factor 1 (HIF-1) inhibitors

The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.

SLCO1B3 genotype

Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R-Rare as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II). 

Aza-epoxy-guaiane derivatives and treatment of cancer

Thalidomide analogs that modulate tumor necrosis factor alpha (TNF&#x3b1;) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

Thalidomide analogs

The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G&#x3e;T/A and 3435C&#x3e;T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.

ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity

A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.

Analogs of thalidomide as potential angiogenesis inhibitors

Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-&#x3b1;) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.

Tetrahalogenated compounds useful as inhibitors of angiogenesis

Growing community of inventors

Fairfax Station, VA, United States of America

William Douglas Figg